Larimar Therapeutics, Inc. (LRMR) Stock

Larimar Therapeutics, Inc. (LRMR) is a Healthcare stock trading at $4.00 (as of 2026-07-24), with a market capitalization of $416.05M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases using a cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is in Phase 1 trials for Friedreich’s ataxia.

Valuation — source: SEC EDGAR (first-party)
Price$4.00
Market Cap$416.05M
Price / Book2.63
FCF Yield-17.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.2
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDEERFIELD MANAGEMENT COMPANY, L.P. ($160.23M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCarole S. Ben-Maimon
Employees65
CountryUS
IPO Date2014-06-19

Related Companies (Business model: Closed-End Fund; 8 closest by market cap; US-domiciled)

  • Liquidia Corporation (LQDA)
  • Lantheus Holdings, Inc. (LNTH)
  • Gladstone Capital Corporation (GLAD)
  • Lightbridge Corporation (LTBR)
  • Comstock Inc. (LODE)
  • LeonaBio, Inc. (LONA)
  • LanzaTech Global, Inc. (LNZA)
  • Lipocine Inc. (LPCN)
LRMR earnings history · LRMR institutional & insider holders · LRMR KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.